Nifty
Sensex
:
:
11095.25
37687.91
203.65 (1.87%)
748.31 (2.03%)

Pharmaceuticals & Drugs - Global

Rating :
71/99  (View)

BSE: 500087 | NSE: CIPLA

713.85
3.45 (0.49%)
04-Aug-2020 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  708.00
  •  718.90
  •  703.20
  •  710.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  6971075
  •  49763.02
  •  734.20
  •  355.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 57,292.22
  • 37.05
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 60,989.64
  • 0.42%
  • 3.63

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.68%
  • 4.33%
  • 16.38%
  • FII
  • DII
  • Others
  • 18.64%
  • 20.88%
  • 3.09%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.81
  • 7.60
  • 4.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.33
  • 5.82
  • 2.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.62
  • 5.08
  • 15.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.13
  • 33.50
  • 32.70

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.55
  • 3.37
  • 3.06

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.80
  • 16.40
  • 14.51

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
4,376
4,404
-1%
4,371
4,008
9%
4,396
4,012
10%
3,989
3,939
1%
Expenses
3,743
3,443
9%
3,613
3,300
9%
3,486
3,310
5%
3,084
3,213
-4%
EBITDA
634
961
-34%
758
708
7%
910
702
30%
905
726
25%
EBIDTM
14%
22%
17%
18%
21%
18%
23%
18%
Other Income
93
95
-2%
72
79
-8%
101
133
-24%
78
170
-54%
Interest
53
45
18%
46
44
4%
46
44
4%
52
35
49%
Depreciation
346
510
-32%
278
293
-5%
283
282
0%
268
241
11%
PBT
328
501
-35%
506
449
13%
681
509
34%
663
620
7%
Tax
86
128
-33%
153
126
22%
201
142
41%
192
174
11%
PAT
242
374
-35%
354
323
9%
480
366
31%
471
447
5%
PATM
6%
8%
8%
8%
11%
9%
12%
11%
EPS
3.01
4.64
-35%
4.39
4.01
9%
5.96
4.55
31%
5.84
5.55
5%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
17,132
16,362
15,156
14,394
13,595
11,345
10,173
8,279
7,021
6,324
5,360
Net Sales Growth
5%
8%
5%
6%
20%
12%
23%
18%
11%
18%
 
Cost Of Goods Sold
5,991
5,784
5,438
5,317
5,090
4,271
3,875
2,953
2,739
2,775
2,453
Gross Profit
11,141
10,578
9,717
9,077
8,505
7,075
6,299
5,327
4,281
3,549
2,907
GP Margin
65%
65%
64%
63%
63%
62%
62%
64%
61%
56%
54%
Total Expenditure
13,926
13,494
12,702
11,918
11,115
9,184
8,040
6,081
5,362
4,955
4,287
Power & Fuel Cost
-
335
299
252
246
228
219
233
235
199
92
% Of Sales
-
2%
2%
2%
2%
2%
2%
3%
3%
3%
2%
Employee Cost
-
2,857
2,690
2,634
2,434
1,968
1,543
1,036
772
566
290
% Of Sales
-
17%
18%
18%
18%
17%
15%
13%
11%
9%
5%
Manufacturing Exp.
-
1,285
1,221
1,193
1,597
737
644
542
583
628
708
% Of Sales
-
8%
8%
8%
12%
6%
6%
7%
8%
10%
13%
General & Admin Exp.
-
1,096
1,002
868
846
743
638
497
370
289
231
% Of Sales
-
7%
7%
6%
6%
7%
6%
6%
5%
5%
4%
Selling & Distn. Exp.
-
1,281
1,083
1,009
819
739
680
466
468
387
326
% Of Sales
-
8%
7%
7%
6%
7%
7%
6%
7%
6%
6%
Miscellaneous Exp.
-
855
969
646
84
498
441
355
194
112
326
% Of Sales
-
5%
6%
4%
1%
4%
4%
4%
3%
2%
3%
EBITDA
3,206
2,868
2,453
2,476
2,480
2,162
2,133
2,198
1,659
1,369
1,073
EBITDA Margin
19%
18%
16%
17%
18%
19%
21%
27%
24%
22%
20%
Other Income
344
477
358
229
208
166
265
222
140
92
354
Interest
197
168
114
159
207
168
146
34
38
25
28
Depreciation
1,175
1,097
950
1,323
754
505
373
330
312
273
167
PBT
2,178
2,079
1,747
1,222
1,727
1,654
1,880
2,056
1,448
1,162
1,231
Tax
631
570
250
180
332
400
463
544
307
195
244
Tax Rate
29%
27%
15%
15%
19%
24%
25%
26%
21%
17%
18%
PAT
1,547
1,545
1,413
1,013
1,372
1,206
1,401
1,551
1,141
967
1,083
PAT before Minority Interest
1,594
1,510
1,419
1,042
1,395
1,254
1,417
1,551
1,141
967
1,083
Minority Interest
47
35
-6
-29
-23
-48
-16
0
0
0
0
PAT Margin
9%
9%
9%
7%
10%
11%
14%
19%
16%
15%
20%
PAT Growth
2%
9%
39%
-26%
14%
-14%
-10%
36%
18%
-11%
 
EPS
19.21
19.18
17.55
12.58
17.03
14.97
17.39
19.26
14.17
12.01
13.44

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
15,012
14,229
12,544
11,516
10,801
10,050
9,019
7,639
6,666
5,911
Share Capital
161
161
161
161
161
161
161
161
161
161
Total Reserves
14,794
14,002
12,321
11,266
10,558
9,868
8,858
7,478
6,506
5,750
Non-Current Liabilities
4,646
4,259
4,515
1,407
2,418
2,028
1,025
824
697
184
Secured Loans
48
0
0
207
287
317
0
0
15
0
Unsecured Loans
3,782
3,662
3,645
15
22
0
1
3
3
5
Long Term Provisions
121
138
141
145
1,783
1,369
714
558
466
0
Current Liabilities
3,772
3,832
3,389
7,776
3,881
2,564
2,278
1,413
1,699
2,526
Trade Payables
1,948
2,119
1,586
1,476
1,452
980
828
692
721
805
Other Current Liabilities
542
647
909
1,006
655
409
251
490
235
193
Short Term Borrowings
486
436
467
4,970
1,392
910
966
10
523
0
Short Term Provisions
796
630
426
324
382
265
232
221
219
1,528
Total Liabilities
23,762
22,673
20,886
21,049
17,281
14,692
12,321
9,876
9,062
8,620
Net Block
9,547
9,949
9,508
9,368
6,830
6,496
3,610
3,215
3,094
2,011
Gross Block
13,665
12,960
11,371
10,168
9,562
8,676
5,318
4,626
4,241
2,897
Accumulated Depreciation
4,109
3,011
1,610
799
2,732
2,180
1,708
1,411
1,146
886
Non Current Assets
11,335
11,859
12,082
12,208
9,689
9,040
5,537
4,820
4,619
2,696
Capital Work in Progress
676
981
1,683
2,061
581
442
378
371
285
684
Non Current Investment
490
158
137
176
250
397
416
329
367
1
Long Term Loans & Adv.
456
515
544
426
1,861
1,552
979
865
841
0
Other Non Current Assets
167
256
210
177
168
152
155
39
31
0
Current Assets
12,427
10,814
8,804
8,841
7,591
5,652
6,784
5,057
4,443
5,924
Current Investments
2,126
1,102
837
582
390
311
2,117
941
224
245
Inventories
3,965
4,045
3,520
3,808
3,781
2,895
2,387
1,850
1,906
1,513
Sundry Debtors
4,151
3,102
2,582
2,356
1,998
1,639
1,669
1,554
1,491
1,567
Cash & Bank
619
966
638
871
564
176
143
90
96
62
Other Current Assets
1,566
480
418
437
859
631
468
622
727
2,537
Short Term Loans & Adv.
1,150
1,119
808
786
713
595
463
460
534
2,388
Net Current Assets
8,655
6,982
5,415
1,065
3,710
3,088
4,506
3,644
2,745
3,398
Total Assets
23,762
22,673
20,886
21,049
17,281
14,692
12,321
9,876
9,062
8,620

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,691
1,463
2,382
1,741
1,173
1,563
1,398
1,713
1,025
1,043
PBT
2,079
1,669
1,222
1,727
1,654
1,880
2,095
1,448
1,162
1,326
Adjustment
1,269
1,294
1,374
951
630
553
284
397
289
147
Changes in Working Capital
-1,064
-778
235
-429
-719
-561
-520
200
-162
-174
Cash after chg. in Working capital
2,284
2,185
2,832
2,248
1,566
1,872
1,859
2,044
1,289
1,299
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-593
-722
-450
-508
-392
-308
-462
-331
-264
-256
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-1,669
-854
-1,310
-4,523
-941
-1,250
-2,063
-965
-908
-563
Net Fixed Assets
-173
-510
-889
1,487
-534
-437
-693
-460
-602
-520
Net Investments
-1,240
-351
-30
165
-834
-985
-1,567
-464
-306
-184
Others
-256
7
-391
-6,175
427
173
196
-41
-1
141
Cash from Financing Activity
-349
-385
-1,326
3,104
165
-266
718
-753
-83
-472
Net Cash Inflow / Outflow
-326
223
-254
322
397
48
53
-6
34
9
Opening Cash & Equivalents
853
610
858
546
176
143
90
96
62
53
Closing Cash & Equivalent
508
853
610
858
564
176
143
90
96
62

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
186
176
155
142
133
125
112
95
83
74
ROA
6%
7%
5%
7%
8%
10%
14%
12%
11%
13%
ROE
10%
11%
9%
13%
12%
15%
19%
16%
15%
21%
ROCE
12%
10%
8%
13%
15%
19%
24%
20%
18%
24%
Fixed Asset Turnover
1.80
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
Receivable days
55
68
62
58
58
59
70
78
87
115
Inventory Days
61
91
91
100
106
94
92
96
98
98
Payable days
59
57
47
49
52
45
49
51
56
69
Cash Conversion Cycle
57
102
106
109
112
107
114
124
129
144
Total Debt/Equity
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
Interest Cover
13
16
9
9
11
14
63
39
47
48

News Update


  • Cipla gets DCGI’s nod to launch Ciplenza in India to treat mild to moderate COVID-19
    25th Jul 2020, 08:48 AM

    The company will commercially launch Ciplenza in the first week of August priced at Rs 68 per tablet.

    Read More
  • Cipla all set to launch Favipiravir
    24th Jul 2020, 13:17 PM

    An off-patent anti-viral drug, Favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for treatment of COVID-19 patients, especially in mild and moderate cases

    Read More
  • Cipla, Amgen settle case involving generic cinacalcet hydrochloride tablets
    20th Jul 2020, 12:07 PM

    The resolution entitles the company and its affiliates to continue importing, marketing, and selling its generic cinacalcet hydrochloride tablets in the United States

    Read More
  • Cipla gets USFDA's nod for Icatibant Injectable Pre-Filled Syringe
    14th Jul 2020, 08:56 AM

    The company’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is APrated generic version of Shire’s Firazyr

    Read More
  • Cipla launches generic version of antiviral drug remdesivir
    9th Jul 2020, 09:15 AM

    Cipremi is priced at Rs 4,000 per 100 mg vial

    Read More
  • Cipla, Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs
    29th Jun 2020, 12:50 PM

    Empagliflozin is approved for glucose-control in patients with type-2 diabetes

    Read More
  • Cipla to price generic version of antiviral drug remdesivir at less than Rs 5,000 per vial
    24th Jun 2020, 14:11 PM

    The drug will be priced at less than Rs 5,000 per vial for injection 100 mg -- amongst the lowest pricing for remdesivir globally

    Read More
  • Cipla launches remdesivir under brand name CIPREMI
    22nd Jun 2020, 08:54 AM

    The USFDA issued a EUA to Gilead Sciences Inc. for emergency use of remdesivir for the treatment of hospitalized 2019 COVID-19 patients

    Read More
  • Roche Pharma India expands partnership with Cipla
    18th Jun 2020, 12:30 PM

    Roche Pharma India has signed a distribution agreement with Cipla

    Read More
  • Cipla signs agreements to acquire 21.85% stake in GoApptiv
    10th Jun 2020, 10:06 AM

    The company will strengthen its partnership with GoApptiv so as to enable widening reach of its key brands in the Tier 3+ towns

    Read More
  • Cipla reports 33% fall in Q4 consolidated net profit
    30th May 2020, 15:23 PM

    Total income of the company decreased by 0.67% at Rs 4469.37 crore for Q4FY20

    Read More
  • Cipla gets USFDA’s final approval for Dihydroergotamine Mesylate Nasal Spray
    21st May 2020, 09:06 AM

    The company is the first approved applicant for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla’s product

    Read More
  • Cipla files ANDA for generic version of GSK’s Advair Diskus
    18th May 2020, 10:06 AM

    The company had recently announced the successful completion of its Phase-3 clinical end-point study for the product in the first attempt

    Read More
  • Cipla reports fall of 33% in Q4 consolidated net profit
    16th May 2020, 15:35 PM

    Total income of the company decreased by 0.67% at Rs 4469.37 crore for Q4FY20

    Read More
  • Cipla inks pact with with Gilead Sciences
    13th May 2020, 09:26 AM

    This agreement is part of company’s efforts to enhance global access to lifesaving treatments for patients affected by the pandemic

    Read More
  • Cipla gets EIR from USFDA for API manufacturing facility in Bangalore
    9th May 2020, 09:21 AM

    The agency had conducted inspection from January 20, 2020 to January 24, 2020

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.